Publication: 3632

Publication: 3632

Tumor immunogenomic features determine outcomes in metastatic colorectal cancer patients treated with standard-of-care combinations of bevacizumab and cetuximab

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Clin Cancer Res vol 28 (8) 1690-1700

Year:: 2022
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: Alliance-data-source,-internal-user
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 11

Parents:: 3261 3633
Children:: None

Program:: TRP
Primary Committee:: Correl Sci NOS
Sec. Committees:

Pharmas:: Bristol Myers Squibb (BMS), Genentech, Pfizer, and Sanofi
Grants:: U10CA180821, U10CA180882, U24CA196171, P30CA014089, UG1CA180830, UG1CA233253, UG1CA233327, UG1CA233373, U10CA180820 (ECOG-ACRIN), U10CA180888 (SWOG)

Corr. Author:
Authors:: Federico Innocenti Akram Yazdani Naim Rashid Xueping Qu Fang-Shu Ou Scott Van Buren Monica Bertagnolli Omar Kabbarah Charles David Blanke Alan P. Venook Heinz-Josef Lenz Benjamin G. Vincent

Networks:: CA011, CA824, LAPS-MA036, LAPS-MN026, LAPS-NC007, OR013

Study: Alliance-A151813
Multiple Studies, or Legacy Studies in Alliance Study:: CALGB-80405
Phases:: N/A, 3

Keywords:: CALGB/SWOG 80405, immune, signatures, overall survival, cetuximab, bevacizumab